Medically Reviewed by Stephanie S. Gardner, MD on November 08, 2022
New Oral Drug for Plaque Psoriasis

New Oral Drug for Plaque Psoriasis

1/9

Deucravacitinib (Sotyktu) is an FDA-approved drug that you take by mouth once daily. It’s designed to help adults with moderate to severe plaque psoriasis. Some experts believe it’s as effective as injectable biologics on the market with fewer side effects. 

Combining Phototherapy and Topical Treatment

Combining Phototherapy and Topical Treatment

2/9

Targeted UV-based phototherapy and topical calcipotriene cream are each commonly used psoriasis treatments. But in a recent study, researchers combined the two treatments. They found that if you apply the ointment and get phototherapy, it can better reduce plaque psoriasis, compared to when phototherapy is used alone. 

New Type of Topical Approved 

New Type of Topical Approved 

3/9

The FDA approved roflumilast cream 0.3% (Zoryve) to treat mild, moderate, and severe plaque psoriasis. The once-daily steroid-free cream is the first phosphodiesterase-4 (PDE4) inhibitor cream approved to treat the scales and itching of psoriasis. An oral PDE4 inhibitor, apremilast (Otezla), is already widely used to treat psoriasis. 

New Topical Spray

New Topical Spray

4/9

AKP-02 is a drug in development designed to be used as a topical spray. It contains a mix of glucocorticosteroids and a form of vitamin D. AKP-02 is for those who have mild to moderate plaque psoriasis. Currently, the drug is in a phase III clinical trial. 

Oral Drug Use Expanded for All Disease Levels

Oral Drug Use Expanded for All Disease Levels

5/9

The FDA recently expanded the use of apremilast to all levels of psoriatic disease. This means that if the medicine is suitable for you, you can use it for all disease stages – mild, moderate, and severe plaque psoriasis. It’s especially good for people who have psoriasis in hard-to-treat areas.

Umbilical Cord Stem Cell Therapy

Umbilical Cord Stem Cell Therapy

6/9

Human umbilical cords contain stem cells called mesenchymal stem cells (MSCs). These cells are strong and have self-renewing properties. In one small study, 17 people with psoriasis were given IVs of umbilical MSCs. They did not have side effects during treatment. At a 6-month follow-up, around 40% saw improvements. There needs to be more research on the potential use of stem cell therapy for psoriasis. 

New Biosimilar in the Works

New Biosimilar in the Works

7/9

Two phase III trials are looking at a biosimilar to ustekinumab (Stelara). APB-64 would be a biosimilar IL-12 and IL-23 antagonist treatment for moderate to severe plaque psoriasis. Biosimilars are typically cheaper versions of biologic drugs. 

New Nonsteroidal Topical Cream

New Nonsteroidal Topical Cream

8/9

Tapinarof cream 1% (Vtama), a once-daily topical nonsteroidal cream, is the first of its kind designed to treat mild to severe plaque psoriasis. In two 12-week studies, 4 in 10 people saw symptoms disappear after 12 weeks of therapy. In fact, symptoms didn’t come back for up to 4 months after the trial. The studies also show the drug may be suitable and safe for long-term use.

Best Phototherapy Combinations Studied

Best Phototherapy Combinations Studied

9/9

An analysis compared various phototherapy treatment combinations. All were found to be better at improving psoriasis symptoms than one therapy alone. But some stood out more than others. Researchers found combinations and variations of phototherapy with calcium and vitamin D derivatives to be most effective. 

Show Sources

IMAGES PROVIDED BY:

  1. Douglas Sacha / Getty Images
  2. Left: Voisin / Phanie / Science Source; Right: Tim Grist Photography / Getty Images
  3. Iri-s / Getty Images
  4. Zyabich / Getty Images
  5. Science Source
  6. Professor Pietro M. Motta & Enrico Vizza / Science Source
  7. LL28 / Getty Images
  8. grublee / Getty Images
  9. Mensent Photography / Getty Images

 

SOURCES: 

National Psoriasis Foundation: “FDA Approves Sotyktu for Psoriasis.”

Jofskin.org: “Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent.”

The Journal of the American Medical Association: “Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.”

Journal of Dermatological Treatment: “Combination of targeted UVB phototherapy and calcipotriene versus targeted UVB alone in psoriasis: systematic review and meta-analysis of randomized controlled trials.”

Signal Transduction and Targeted Therapy: “Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study.”

Psoriasiscouncil.org: “Amgen Announces New Otezla (Apremilast) Data.”

ClinicalTrials.gov: “A Phase III Study in Subjects With Mild to Moderate Psoriasis. (AKVANO-AKP02),” “A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis.”

Annals of Medicine: “Assessment of efficacy and safety of UV-based therapy for psoriasis: a network meta-analysis of randomized controlled trials.”